Navigation Links
Patent for Making Combination Chemotherapy Work Better
Date:3/24/2009

SAN JOSE, Calif., March 24 /PRNewswire/ -- Patent 7,507,704 issued on 03/24/09 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses an improved method of treating lung, brain, pancreatic, breast and colon cancers that are driven by a mutation known as HER1 overexpression (also called EGFR or c-ErbB-1). The patent presents a case for why today's concurrent HER1 blocker / S-Phase cytotoxic protocols achieve only a fraction of the potential inherent in the combination of the underlying drugs. Novel synergistic protocols are provided.

All proliferating cells progress through 4 distinct phases, in sequence, G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's irinotecan or Eli Lilly's gemcitabine, are capable of killing virtually all cells that are in the S-Phase, however, less than one third of cancer cells are typically in the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor. "Mechanistically, HER1 blockers, such as Genentech's erlotinib, AstraZeneca's gefitinib, ImClone's cetuximab and Amgen's panitumumab arrest and aggregate HER1 overexpressing cancer cells in the G1-Phase. This results in S-Phase depletion, greatly reducing the number of cancer cells killed by the S-Phase cytotoxic." The patent provides a crucial modification to the protocols by adding existing drugs to provide S-Phase enrichment at the appropriate time, while using the HER1 blocker to inhibit tumor regrowth between administrations of S-Phase cytotoxic.

Patent 7,507,704 is the third in a series of patents awarded to Mr. Zamoyski for cancer specific S-Phase enrichment relative to administrations of S-Phase cytotoxic chemotherapy. "With less than one third of cancer cells in the S-Phase, today's cytotoxic protocols only extend life expectancy by a few months. Doubling the number of cancer cells in the S-Phase would provide a way of indefinitely keeping most cancers in check. Tripling the number, wh
'/>"/>

SOURCE NexGen Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
2. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
3. Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
4. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
5. VIASPACE Granted US Patent
6. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
7. VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
8. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
9. InterMune Announces Issuance of U.S. Patent for ITMN-191
10. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
11. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... MINNEAPOLIS, MN , April 30, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has commenced ... addition, BioAmber expects to grant the underwriters a 30-day ... of the shares of common stock offered in the ... and there can be no assurance as to whether ...
(Date:4/30/2015)... ALEXANDRIA, Va. , April 30, 2015 ... provides senior debt to life sciences and healthcare services ... senior secured term loan agreement with Celula, Inc., a ... diagnosing major diseases, enabling better patient care and improved ... continue the development and expand the commercialization of its ...
(Date:4/30/2015)... MA & Budapest, Hungary (PRWEB) April 30, 2015 ... only web-based electronic lab notebook with integrated protocols ... in providing chemistry software solutions and consulting services ... led to the development of Labguru’s newest feature: ... set of deep domain features for biologists, bio-chemists, ...
(Date:4/30/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) a ... biosimilar therapeutics including high value and difficult to ... previously announced underwritten public offering of 6,750,000 shares ... price of $15.50 per share. This includes the ... option to purchase up to 750,000 additional shares ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Oxford Finance Provides $10 Million Debt Financing to Celula 2Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... 6 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced ... any and all of its outstanding 3.0% Convertible,Notes due ... Time on,October 4, 2007, unless extended. The tender offer, ... the related letter of transmittal, is not,subject to the ...
... and ST. LOUIS, Sept. 6 Resource ... (GPO) serving St. Louis-,based Sisters of Mercy ... Elekta,enabling members to begin purchasing Elekta,s innovative ... ) Under the agreement, Mercy will ...
... BARCELONA, Spain, Sept. 6 Elekta, a ... solutions, will showcase,the latest advances in radiotherapy, ... European Society of Therapeutic Radiation,Oncologists (ESTRO) 2007 ... 2,000 physicists, radiotherapists, oncologists and other health ...
Cached Biology Technology:NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 2NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 3NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008 4Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 2Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability 3
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... has been a focal point of recent climate change research ... than the larger Antarctic ice sheet. Yet while the southern ... clear how much this is contributing to rising sea levels, ... research was defined at a recent workshop organised by the ...
... overlooked and undervalued protein, sarcospan, just got its ... show that adding it to muscle cells might ... In Duchenne muscular dystrophy (DMD), the mutated dystrophin ... glycoprotein complex. And without this anchoring, muscle cells ...
... day be mended using a novel scaffold developed by MIT ... heart cells or stem cells seeded onto such a scaffold ... be used to treat congenital heart defects, or aid the ... scaffold would be gradually absorbed into the body, leaving behind ...
Cached Biology News:What is really happening to the Greenland icecap? 2MIT: Mending broken hearts with tissue engineering 2
... CGH Genomic Labeling Systems are a high-performance ... genomic DNA samples for array-based Comparative Genomic ... direct labeling formats, the BioPrime Plus Array ... solution to your genomic labeling needs. ...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
... Neural Stem Cell Expansion Kit - Monolayer is ... NSC expansion as a monolayer in a serum-free ... Plus Media Supplement, which has been optimized for ... al . (1996) Genes & Development 10 ...
... DNA Polymerase I from E. ... polymerase. The enzyme also contains ... The 5'?3' exonuclease activity enables ... and gaps in the DNA ...
Biology Products: